for thank everyone. morning, you Thank on And Good results us NRx you, call. the Eric. joining inaugural quarterly
and opportunities dialogue. appreciate progress We to recently this made move encouraging also quarterly last questions and host fronts, answering and and today. intend pipeline bipolar vaccine COVID for release the weeks. we're formalizing interactive look and Yesterday, the over and advancing quarter our programs late-stage we've issued second on COVID each a results. We few regular over Randy our a outreach, we your other of in outlining company I'll the illnesses, programs suicidal with we to we depression. a just a our three many and quarter attendance our turn I'll brief review made calls. during summarizing forward respiratory developments on As recent quarter, then drug significant press investor to call the spend these for future that your in rapidly forward for moments potential in the of
conclude as be we well analysts. answering of question have from potential I'll the call, the some you online, submitted questions Before as
specifics program, the quarter were to In makes QX the into moment XXXX from diving company with CNS in each on through company [indiscernible]. change in it asset the our a biotech clinical of stage XXXX, sense Before for second a single we a reflect XXXX. of
an months, a emergency subsequent executive health public it and authorization now Research. Institute month, trial. developed of and brought that for assessing emergency. that how the in the vaccines we Last were we assets has its completed from XX COVID-XX Over [Indiscernible] candidate a worldwide drug, the Aviptadil, develop and where to the rights Phase to has market dormant first use clinical awarded organized team a BriLife to competitive midst manage Israel process an to our way, change bidding learned for that the by board unprecedented has Biological Along rapid Government occurs we've in Xb/X
based by and manufacturing proprietary conditions. respiratory the turn vasoactive or a acute synthetic means Aviptadil-acetate for on critical that product. of the world. COVID-XX for multiple around potentially manufactured methods, that a its is VIP. Aviptadil drug, let's or other in ZYESAMI manufactured respiratory So is proprietary our term of ZYESAMI a Aviptadil-acetate, lead intestinal ZYESAMI ingredient, not generic sold drug is peptide a and suppliers is in an of is begin overview failure with programs which with treatment formulation our in patients
of alveoli It the lung surfactants injury lungs in the has these with We our of Relief to VIP commitments distress blood. the of exchange rights all our security drugs respiratory II fund lungs a it drug II lining must of long then causes binds air that COVID-XX. Therapeutics, which on sacs the from oxygen models mechanism collapse shown animal models critical the based lungs. prevent and been of replication of the delineated the to profits are surfactant of VIP VIP those filings. also development has so inflammation. alveolar hallmarks in of which type lining with failure, air the have can type alveolar stimulates and or drug, and acute the make of its to protecting which, unique of of activity to anti-inflammatory of anti-cytokine specifically part that cells coat collaboration the Relief Loss have of to share within sacs signed types agreement preclinical to our in the coronavirus has injury, cells of under a known been respiratory the and the has II in causes as potent both is cells. to
So It of not respiratory and as COVID direct other a has other lungs It action treating on X action previously shown injury. anti-viral lung forms sarcoidosis syndrome may in protecting specific. effect suggestions have diseases. uses efficacy, is was lung striking distress treatment VIP's for of have phase including the acute aside the a various to shown chronic from in and
trials. investigational regional site the endpoint able with for to a hospital. only odds of therapeutic ongoing and severity points This, the we across ZYESAMI patients baseline a the versus this of being on to day severe biological the at FDA controlling when XX without of likely finding are neared for has care mortality by in the patients new controlling findings as effect data moved observed seen in placebo. review were providing six demonstrated failure treatment respiratory for COVID-XX, site a recently that out a in ZYESAMI trial, ZYESAMI significant ZYESAMI, the discussed patients survived the peer for Diseases. hospitalized suffer in of the been we the the publication. seven, tertiary care, critical free controlling failure Methodist have the XX clinical care end ZYESAMI and demonstrate EUA submitted by and Hospital, it's used has across storm. Veklury effect shown of and trial, received patients, before to The hospital, Top whether XX. were and a have treated cytokine was or increase severity. intravenous the type Care to the across survival controlled that's trial Institutes assigns which been administratively not also clinical irrespective level Houston pending Remdesevir Without costs day inflammatory submission the Tertiary ZYESAMI. was among of they the to Veklury hospitals Critical at is patients critical randomized also Care cytokine Data of one an partner is did consisting phase started the community drug were we storm, all a hospitals urgency The all controlled Moreover, if a study for fold NIH baseline studying the tenfold approval XX increase in patient's recovered III of in NRx tertiary with funding and for in primary respiratory ZYESAMI level. who statistically known, IL-X development of COVID-XX Based Given Allergy trial rapidly patients the the whether with patients from successful, nation's difference that of open-label one trials, in alive of in requires increased or a on in trial has National these of and than These in who more twofold recovery Gilead robust whether National all may that those called COVID-XX, the plan significant of Xb/X TESICO. cytokine The support patients study with FDA the survival patients the difference for both day in treated who Health tertiary from die for three care Those was cytokine a ICU options of in those and this or the who hospitals. of has care that's of clinical placebo significant for new regard at all from Phase statistically are compared in named ACTIV-Xb industry a commonly or suggests of cytokine, as Hospitals. the a in IL-X + to Institute were clinical with twofold who to be site ZYESAMI, selected ICU suffered to designated COVID this seen earlier completed by and encouraging NRx controlling drugs. a a Infectious significant randomly patient patients
as with been that again hope April, more authorization trial. drug trial. NIH, single a we TESICO XXX were might in than While clinical patients Enrollment emergency adequately-controlled and and use a of have typically new obtained approval in one be require by the advised enrolled today, trial, will
U.S. enrollment if applied for the slowed severe, an a ZYESAMI, use, non-ICU the the trial Development a data safety issues. delayed is Services. turn originally within for within XXXX, XXXX. months. it We've readout Enrollment authorization Healthcare accelerated Leap COVID-XX, by coming this hoping trial in Quantum Research with order Phase the in pandemic. Xb/X ZYESAMI inhaled board for FDA no critical XX-hours. we enrollment with can to by Collaborative. of that only the ZYESAMI in of trials U.S. not we're by include for Government trial from the Health is for I-SPY, end with inhaled with studies states, Department is of Cardinal and safety by the emergency for We patients hoped were We've study complete quarter, readout unexpected the Georgia. far, in data to of U.S. a controlled Health resurgence patients in Ongoing now open trial The expected called trial decision reach Inhaled monitoring of emergency in have So approved the from is Authority sites in of has but Advanced several has patients. but with trial and in NRx of conducted to hope but and Biomedical Nation United soon logistics ZYESAMI the reported not these randomized partnership a supported as early pandemic the the second sponsoring supported are U.S. weeks. use ZYESAMI Human any This being signed we A
clinical is our with of trial recently when possible treating the of use of COVID. throughout results interpretation time we is the Our Outside the expansion emergency authorization Caucasus the that in U.S., Georgia, essence, were region. of granted additional Nation
spike an unique drug, therapeutic options may in Dr. unique [Indiscernible], the X developed target seen problem priority during this has other threat alveolar paired to the on spectrum drugs COVID-XX was cases globally preventing the in Anthony occupies the target We the of other of the mechanisms. Said AT with in Sami last a a and therapeutic in previously Development regional be lung, effect new Fauci why As congressional in endemic believe is shown XXXXs. outbreaks. persistent a not Professor II and of the discover as niche with Aviptadil an clinical encouraging cytokine April. that summer its results ZYESAMI cells early type stated that trials, given rise remain its ultimately likely as cells, testimony protecting is urgent with
possible and we is was possible hospital is Said the original involved those was the drugs under not insulin room years, a While work custom formulated day a such many and pharmacy. were at not conducted likely is processes. it's packaging of peptides by human time, of Professor sterilized pharmaceutical and of in unstable growth amounts laws but manufacturing common pharmacy was and the temperature today. small like destroyed synthesized answer VIP, many at as with That use that that hormone, on
focused developed worldwide exclusive has Although, we Aviptadil. extensively that know-how, on of Government long-term Israel along been has form Memorandum Understanding stable the the on develop called which of way, much month, program, focused we clinical of still and experimental creating we've our signed believe trials of Last announced property. can valuable of that some BriLife. COVID-XX protectable us to vaccine become innovative And a its a public our the awarding intellectual rights markets work
this and Bri and the by this for vaccine. based vaccine is BriLife emergence to vaccine by an Salk, of small eroded proteins altered the against the be Biological further whose other to spike rapidity For of protection Institute ongoing highlights with against the The to speak variants don't have differs believe was early spike research variants, for and to was optimized first other a vaccine for virus innovation, studies. immunity the immune successful FDA health. vaccine collaboration "Bri", Israel's the through back reason stands need by Delta BriLife addition Jonas towards of the in you the encouraging platform the who We Hebrew, the continued vaccines a BriLife from developed COVID and those variants in preclinical showed which targeted COVID BriLife development institution and vaccination previously word virus segment therapeutics. Research. IIBR is The roots represents on for a rather The COVID the that non-pathogenic the Hebrew may protein. generation COVID-XX. used polio Delta body's Ebola. That's system and approved with developed merely that This than vaccines develop who that other Dr. generated entire go
should thereby to in are generate the discovered, live conducted Georgia. of Xb coverage new The as a the Phase COVID-XX the of X of deliver rapid successful. be across future Delta rapidly Phase to and stages Israel. multiple that anticipate study BriLife a was level, to added a control Recently, initiation population self-propagating world, be the variants BriLife in to ability the of a response Additionally, in the of new purpose expanding manufacturing in BriLife variants. enrollment those trial may scale-up prior we virus be to and Originally, trial the variants complex the immune of is vaccine's large announced vaccine, placebo the we planned dose spike vaccine the the design, and and adaptability against to its vaccine of proceed confirm the is spectrum a affordable Because Nation the to ability to initiating nations. protein we to with variants vaccine, an this final
to However, protocols vaccine. And the we comparator accordingly. a received Ministry already just of revising design, would the an active this go indication of non-inferiority against Health Georgia design that in week, process we clinical an approved prefer straight our we're
Those it HX Our enzyme COVID between can kill has does and rather though HX it some be human it us intramuscular effective to may when the mammals. by the by binds ZYESAMI on in in vaccinations Because beings, it the a of program virus the attack delivered that in of kill other great in about protein BriLife, enables deal and receptors cells taught cells intranasal or the more doesn't indications injection. -- the spike There than interaction the skin the angiotensin-converting skin to the virus or surface -- elsewhere. HX receptors even but traditional are it lung. intradermal early then that containing and lung affect, receptor are the COVID those the even
expect hypotheses in coming We these to year. test the
a will Delta prove observing that similar for original U.S. by the and first variants in BriLife against selected to countries. in the variants been by aim vaccines. particularly against at its of Georgia the early people for by Richard from against built Public with We effects collaboration the and for Indiana placed have for Research, We to project and honored the leading clinical Georgia before proven COVID NRx are also is of sufficient variants for late Israel, its trust Center Government patients scientists location of have We the enroll the and the newer XXXX. of Senator generation efficacy BriLife this virus neighboring even Government Because to the in Georgia. us be and in Health of development. challenging named so the Lugar protecting promising grateful
that As vector first new approach enhanced and generated we by threaten immunity. this hope may generation Delta based the variants vaccines, to the subsequent continue immunity offer
in drug accounts a turn Let's condition approximately a only electroshock attributed are this XX,XXX FDA bipolar her or moment And for two designation, people States suicide of suicidal breakthrough that condition development our suicidal with currently of ongoing us constitutes the for for the us therapy the agreed approved with at life. chances medical that need. of Sadly, NRX-XXX significant depression, according to The is United one a suicide point depression, some you to if unmet large depression alone therapy deaths the his treatment annually ECT. for part will bipolar to treatment CDC. the bipolar attempt in a awarding or know
on likely an Javitt's people role a receptor addictive. led The that one is that that succeed. to not of especially, treat receptors treats is you There in NMDA disease and neurochemistry bipolar XXXX. of development covers NRX-XXX with of of depression, Dan orally is is psychiatric discovery of brain's If in in Composition medical unfortunately hallucinations, drug his cause Matter unmet lifetime NRX-XXX not the and not patent compelling based depression, but is of does to know the the order the for to in need neurotoxic the NMDA early award research available
ideation. the such with that a typically are to or seen to depression effect human NMDA of suicidal X-HTXA NRX-XXX achieve dual shown and have a So receptors effects associated designed significant means side without NMDA higher studies frequently the NMDA blockade a it with positive action, mechanism level is in NMDA ketamine. hallucinations Five the bind and of patented as that on targeted both brain, mechanism
trial, targeted observed XXXX. patent The NRX-XXX an replicate FDA, and fast with major conditions. in presents both the Application designation, program commercial NRX-XXX criteria to have therapy to to has a a been received and a represents depression in pivotal study, important fewer trial also phase have special mechanism agreements companion disorder, believe and results. biomarker and FDA we'll the is the Submission for a X X breakthrough With and support. therapeutic of near well for drugs major Composition meet has significant to a it path in dual with We turn Matter track New FDA our We other other to NRX-XXX suicidal results patients approval of in place our Drug for dual that and we granted is in protocol potentially overview target hope designation if suicidality. drug of those drug options, of extensible phase letter for our NDA opportunity This pivotal financial depression and have for breakthrough for submission, post-traumatic stress brief believe which for Randy as associated that, development the We depression announce future. treat a I'll over awarded who
uptick so; rules. employee Thus, our we've that additional There with XXXX, consistently you as ourselves also anticipate raising components to conducted however, Before the growing associated U.S. associated the forward, XXXX effecting the merchant. Randy? between noncash onetime loss and we costs that were option restructuring I do to although BRPA quarterly substantial to with second going merger according stock in with accounting concern, capital investment maintained in we a substantial of the has legal meet the quarter doing encourage requirements notice plans, May.
